Tuberculosis is a worldwide health problem that warrants attention given that the current treatment options require a long-term chemotherapeutic period and have reported the development of () multidrug resistant strains. In this study, -butyl and isobutyl quinoxaline-7-carboxylate 1,4-di--oxide were evaluated against replicating and non-replicating H37Rv strains. The results showed that seventeen of the twenty-eight derivatives have minimum inhibitory concentration (MIC) values lower than isoniazid (2.92 μM). The most active antimycobacterial agents were , , , and , which have the lowest MIC values (0.53, 0.57, 0.53, and 0.55 μM respectively). These results confirm the potential of quinoxaline-1,4-di--oxide against to develop and obtain new and more safety antituberculosis drugs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324059 | PMC |
http://dx.doi.org/10.1039/d4md00221k | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!